secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213269
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028
-------------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.
- Net loss $13.6M vs $15.8M in Q1 2025; R&D expense $9.7M vs $12.1M.
- KOMODO-1 first-in-human trial of BBI-940 enrolling patients with ER+/HER2- and TNBC-LAR breast cancer.
- AACR 2026 data showed tumor regression from BBI-940 in ecDNA+ TNBC-LAR and ER+ breast cancer models.
- G&A expense $4.7M vs $5.2M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/0001193125-26-213269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/bold-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer